On Thursday, Jones Trading reiterated its Buy rating on shares of Achieve Life Sciences (NASDAQ:ACHV), with a steady price target of $20.00. The firm's stance comes following the announcement that the Data Safety Monitoring Committee (DSMC) reviewed the ORCA-OL trial and determined it could continue without any modifications. This decision was based on the absence of safety concerns and an excellent overall safety profile for the trial.
The ORCA-OL trial is a key component of Achieve Life Sciences' development program for cytisinicline, a potential treatment designed to help smokers quit. The positive outcome of the DSMC review is seen as a supportive factor for the trial's continuation. According to the analyst, this development reinforces the belief that cytisinicline could offer clinical benefits to individuals seeking to stop smoking.
The analyst's commentary highlighted the significance of the DSMC's findings, noting the importance of the trial's progression for Achieve Life Sciences. The company is reportedly on track to submit a New Drug Application (NDA) in the first half of 2025, aligning with its projected timeline for regulatory progression.
Achieve Life Sciences' commitment to addressing the needs of smokers through the development of cytisinicline is underscored by the latest feedback from the DSMC. The company's focus remains on advancing its clinical program and meeting its strategic milestones in the coming months.
Investors and stakeholders in Achieve Life Sciences may view the recent developments as a reaffirmation of the company's path forward, with the maintained Buy rating and $20.00 price target reflecting confidence in the potential of cytisinicline and the company's overall direction.
In other recent news, Achieve Life Sciences has reported significant developments. The company's second quarter financial results for 2024 revealed a net loss of $8.5 million, despite holding $61.3 million in cash and investments. In a strategic move, Achieve Life Sciences refinanced its debt with Silicon Valley Bank, extending the maturity date to December 2027.
The company has also seen changes in its executive leadership with Richard Stewart taking over as CEO and Thomas B. King appointed as Executive Chairman. This transition is aimed at enhancing the company's potential in licensing and commercial partnerships, particularly as they continue to prioritize their smoking cessation drug, cytisinicline.
On the analyst front, CG Capital maintained an Outperform rating and a $14.00 price target for Achieve Life Sciences, highlighting the company's readiness to move forward and its potential for securing a considerable portion of the market in the smoking and vaping cessation space. Jones Trading also reiterated their Buy rating and $20.00 price target on the company.
Furthermore, Achieve Life Sciences' cytisinicline program has received FDA breakthrough therapy designation for treating nicotine dependence from e-cigarettes. The company is expected to submit a New Drug Application for smoking cessation in the first half of 2025.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Achieve Life Sciences' (NASDAQ:ACHV) financial position and market performance. The company's market capitalization stands at $171.36 million, reflecting investor sentiment towards its potential in the smoking cessation market. Notably, ACHV has demonstrated strong recent performance, with a 19.07% price return over the past month and a 36.9% return over the last year, indicating growing market confidence in the company's prospects.
InvestingPro Tips highlight that ACHV holds more cash than debt on its balance sheet, which could provide financial flexibility as it progresses towards its NDA submission in 2025. Additionally, the company's liquid assets exceed short-term obligations, potentially offering a buffer for ongoing clinical development costs.
However, it's important to note that ACHV is not currently profitable, with an adjusted operating income of -$25.37 million over the last twelve months. This aligns with the InvestingPro Tip indicating that analysts do not anticipate the company to be profitable this year, which is not uncommon for biotech firms in the development stage.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide deeper insights into ACHV's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.